7.51
Bicycle Therapeutics Plc Adr stock is traded at $7.51, with a volume of 231.77K.
It is up +1.62% in the last 24 hours and down -17.29% over the past month.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
See More
Previous Close:
$7.39
Open:
$7.31
24h Volume:
231.77K
Relative Volume:
0.74
Market Cap:
$489.26M
Revenue:
$36.90M
Net Income/Loss:
$-166.28M
P/E Ratio:
-2.2827
EPS:
-3.29
Net Cash Flow:
$-203.53M
1W Performance:
+6.22%
1M Performance:
-17.29%
6M Performance:
-71.87%
1Y Performance:
-67.97%
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Name
Bicycle Therapeutics Plc Adr
Sector
Industry
Phone
011441223261503
Address
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BCYC
Bicycle Therapeutics Plc Adr
|
7.51 | 489.26M | 36.90M | -166.28M | -203.53M | -3.29 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-08-24 | Initiated | Stephens | Equal-Weight |
Sep-06-24 | Initiated | RBC Capital Mkts | Outperform |
Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
Sep-11-23 | Upgrade | B. Riley Securities | Neutral → Buy |
Aug-31-22 | Initiated | Cowen | Outperform |
Jul-28-22 | Initiated | Barclays | Overweight |
Jul-06-22 | Resumed | Canaccord Genuity | Buy |
Apr-13-22 | Downgrade | B. Riley Securities | Buy → Neutral |
Apr-07-22 | Resumed | Cantor Fitzgerald | Overweight |
Feb-14-22 | Initiated | Morgan Stanley | Equal-Weight |
Dec-17-21 | Initiated | SVB Leerink | Outperform |
Dec-09-21 | Initiated | Needham | Buy |
Sep-30-21 | Initiated | B. Riley Securities | Buy |
Apr-20-21 | Initiated | JMP Securities | Mkt Outperform |
Oct-12-20 | Initiated | Cantor Fitzgerald | Overweight |
Jun-12-20 | Initiated | Oppenheimer | Outperform |
Apr-17-20 | Initiated | H.C. Wainwright | Buy |
Nov-14-19 | Initiated | ROTH Capital | Buy |
Sep-11-19 | Upgrade | Goldman | Neutral → Buy |
Jun-17-19 | Initiated | Canaccord Genuity | Buy |
Jun-17-19 | Initiated | Goldman | Neutral |
Jun-17-19 | Initiated | Jefferies | Buy |
Jun-17-19 | Initiated | Piper Jaffray | Overweight |
View All
Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 By Investing.com - Investing.com South Africa
Bicycle therapeutics COO Alistair Milnes sells $16,850 in stock By Investing.com - Investing.com South Africa
Bicycle Therapeutics chief product officer sells shares worth $5,735 - Investing.com
Bicycle Therapeutics CEO Lee Kevin sells shares worth $43,612 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock - Investing.com
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 By Investing.com - Investing.com UK
Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India
Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa
Bicycle Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com India
Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Jefferies cuts Bicycle Therapeutics price target to $42 from $53 By Investing.com - Investing.com South Africa
Bicycle Therapeutics stock holds $33 target, Buy rating at Rodman By Investing.com - Investing.com South Africa
Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com India
Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa
Bicycle Therapeutics stock hits 52-week low at $11.14 By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India
Bicycle Therapeutics reports promising cancer drug trial results - Investing.com India
Bicycle therapeutics CDO Santiago Arroyo sells shares worth $69,646 - Investing.com India
Bicycle Therapeutics CFO Alethia Young sells shares totaling $19,655 - Investing.com
Bicycle Therapeutics exec sells $30k in shares - Investing.com
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares By Investing.com - Investing.com South Africa
Bicycle Therapeutics CTO sells shares worth $60,119 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares - Investing.com
Bicycle Therapeutics CEO Lee sells shares worth $172,952 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CEO Lee sells shares worth $172,952 - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strength - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data - Investing.com
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - Yahoo Finance
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance
Pharmacovigilance and Drug Safety Software Market Size to Reach USD 371.88 Million by 2032, Growing at a 6.76% CAGR – SNS Insider - Yahoo Finance
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India
Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India
Bicycle Therapeutics retains stock target and Buy rating on promising data - Investing.com
Bicycle Therapeutics spotlights cancer treatment targets - Investing.com
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN
BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Oppenheimer backs Bicycle Therapeutics' BRC platform, reiterates $48 stock PT - Investing.com UK
Bicycle therapeutics CEO sells shares worth over $71k - Investing.com
Bayer Reports Positive Safety Data on Parkinson's Disease Drug - Yahoo Finance
Bicycle Therapeutics Plc Adr Stock (BCYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):